Skip to content

Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on PeritoneAl dialySiS

Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on PeritoneAl dialySiS (COMPASS) Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01887262
Acronym
COMPASS
Enrollment
108
Registered
2013-06-26
Start date
2013-07-31
Completion date
2016-07-31
Last updated
2018-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Dialysis, Continuous Ambulatory

Keywords

fluid, edema

Brief summary

Bioimpedance-guided fluid management in peritoneal dialysis patients may provide better protection of residual renal function over 1 year period, compared with management guided by clinical information alone - such as blood pressure, body weight, and physician's physical examination.

Interventions

DEVICEBCM-guided fluid management
PROCEDUREFluid management based on the clinical information alone

Sponsors

Fresenius Medical Care Korea
CollaboratorINDUSTRY
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* age bwten 20 and 75 * peritoneal dialysis \> 4 weeks duration * written consent * daily urine output \> 500 ml

Exclusion criteria

* subjects who are contraindicated to the bioimpedance measurement (pacemaker insertion state, defibrillator state, amputee, prosthesis, metal implants) * pregnant women * subjects who are expected to discontinue peritoneal dialysis with one year * mixed dialysis modality (peritoneal + hemodialysis) * hypoalbuminemic subjects (serum albumin \< 3.3 g/dL) * high blood pressure (\> 160/100 mmHg despite antihypertensive medications) * severe heart failure (NYHA FC III, or IV)

Design outcomes

Primary

MeasureTime frameDescription
delta GFRbaseline and 12th monthchange of glomerular filtration rate from baseline to the 12th month

Secondary

MeasureTime frameDescription
time to anuriaover 12 monthstime to the anuric state (urine volume \< 100cc/d)
echocardiographic parameters12 months periodparameters obtained by echocardiographic measurements such as left ventracular mass index (LVMi), E/e' ratio, left vetricular end-diastolic volume (LVEDP), left ventracular ejection fraction (LVEF), left atrial volume indx (LAVI)
GFRat 12th monthglomerular filtration rate measured by urine collection, calculated by the mean of creatinine and urea clearance
cardiovascular eventover 12 monthsfatal and nonfatal cardiovascular events - acute myocardial infarction (AMI), stroke, unstable angina, amputation, cardiovascular revascularization
BCM parametersbaseline and 12th monthparameters measured by body composition monitoring (BCM), such as overhydration(OH), extracellular water (ECW), extracellular-to-intracellular water ratio (ECW/ICW)
BP12th monthsystolic, diastolic blood pressure, pulse pressure

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026